BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22425895)

  • 1. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.
    Bains T; Heinrich MC; Loriaux MM; Beadling C; Nelson D; Warrick A; Neff TL; Tyner JW; Dunlap J; Corless CL; Fan G
    Leukemia; 2012 Sep; 26(9):2144-6. PubMed ID: 22425895
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient.
    Kawashima-Goto S; Imamura T; Seki M; Kato M; Yoshida K; Sugimoto A; Kaneda D; Fujiki A; Miyachi M; Nakatani T; Osone S; Ishida H; Taki T; Takita J; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S; Hosoi H
    Int J Hematol; 2015 Apr; 101(4):411-6. PubMed ID: 25430085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
    Degryse S; Bornschein S; de Bock CE; Leroy E; Vanden Bempt M; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J
    Blood; 2018 Jan; 131(4):421-425. PubMed ID: 29187379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.
    Bodaar K; Yamagata N; Barthe A; Landrigan J; Chonghaile TN; Burns M; Stevenson KE; Devidas M; Loh ML; Hunger SP; Wood B; Silverman LB; Teachey DT; Meijerink JP; Letai A; Gutierrez A
    Leukemia; 2022 Jun; 36(6):1499-1507. PubMed ID: 35411095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early T-cell precursor leukemia/lymphoma in adults and children.
    Allen A; Sireci A; Colovai A; Pinkney K; Sulis M; Bhagat G; Alobeid B
    Leuk Res; 2013 Sep; 37(9):1027-34. PubMed ID: 23827350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.
    Broux M; Prieto C; Demeyer S; Vanden Bempt M; Alberti-Servera L; Lodewijckx I; Vandepoel R; Mentens N; Gielen O; Jacobs K; Geerdens E; Vicente C; de Bock CE; Cools J
    Blood; 2019 Oct; 134(16):1323-1336. PubMed ID: 31492675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.
    Spinella JF; Cassart P; Richer C; Saillour V; Ouimet M; Langlois S; St-Onge P; Sontag T; Healy J; Minden MD; Sinnett D
    Oncotarget; 2016 Oct; 7(40):65485-65503. PubMed ID: 27602765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression.
    Yuan S; Wang X; Hou S; Guo T; Lan Y; Yang S; Zhao F; Gao J; Wang Y; Chu Y; Shi J; Cheng T; Yuan W
    Leukemia; 2022 Feb; 36(2):370-382. PubMed ID: 34465864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
    Yin C; Sandoval C; Baeg GH
    Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of tofacitinib to achieve an objective response in a
    Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of the absence of biallelic deletion at the
    Farah N; Kirkwood AA; Rahman S; Leon T; Jenkinson S; Gale RE; Patrick K; Hancock J; Samarasinghe S; Linch DC; Moorman AV; Goulden N; Vora A; Mansour MR
    Haematologica; 2018 Jul; 103(7):e288-e292. PubMed ID: 29519867
    [No Abstract]   [Full Text] [Related]  

  • 12. Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia.
    Xi Y; Li J; Zan L; Wang J; Wang G; Ning Y
    Hum Pathol; 2013 Jun; 44(6):1011-6. PubMed ID: 23260326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
    Uckun FM; Pitt J; Qazi S
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):37-48. PubMed ID: 21070101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
    Kameda T; Shide K; Shimoda HK; Hidaka T; Kubuki Y; Katayose K; Taniguchi Y; Sekine M; Kamiunntenn A; Maeda K; Nagata K; Matsunaga T; Shimoda K
    Int J Hematol; 2010 Sep; 92(2):320-5. PubMed ID: 20697856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK3
    Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
    Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia.
    Jotta PY; Ganazza MA; Silva A; Viana MB; da Silva MJ; Zambaldi LJ; Barata JT; Brandalise SR; Yunes JA
    Leukemia; 2010 Jan; 24(1):239-42. PubMed ID: 19829307
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.
    Grossmann V; Kern W; Harbich S; Alpermann T; Jeromin S; Schnittger S; Haferlach C; Haferlach T; Kohlmann A
    Haematologica; 2011 Dec; 96(12):1874-7. PubMed ID: 21828118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-ALL treated according to the NOPHO ALL-1992 and ALL-2000 protocols.
    Fogelstrand L; Staffas A; Wasslavik C; Sjögren H; Söderhäll S; Frost BM; Forestier E; Degerman S; Behrendtz M; Heldrup J; Karrman K; Johansson B; Heyman M; Abrahamsson J; Palmqvist L
    Pediatr Blood Cancer; 2014 Mar; 61(3):424-30. PubMed ID: 24424791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
    Zenatti PP; Ribeiro D; Li W; Zuurbier L; Silva MC; Paganin M; Tritapoe J; Hixon JA; Silveira AB; Cardoso BA; Sarmento LM; Correia N; Toribio ML; Kobarg J; Horstmann M; Pieters R; Brandalise SR; Ferrando AA; Meijerink JP; Durum SK; Yunes JA; Barata JT
    Nat Genet; 2011 Sep; 43(10):932-9. PubMed ID: 21892159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.
    Bergmann AK; Schneppenheim S; Seifert M; Betts MJ; Haake A; Lopez C; Maria Murga Penas E; Vater I; Jayne S; Dyer MJ; Schrappe M; Dührsen U; Ammerpohl O; Russell RB; Küppers R; Dürig J; Siebert R
    Genes Chromosomes Cancer; 2014 Apr; 53(4):309-16. PubMed ID: 24446122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.